Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Bio USA participation
30
2024.05
Kangstem Biotech will be attending the 'BIO International Convention 2024'(BIO USA) in San Diego, USA from June 3rd to 6th.
Kangstem Biotech will be attending the 'BIO International Convention 2024'(BIO USA) in San Diego, USA from June 3rd to 6th. We will hold partnership meetings with more than 20 multinational pharmaceutical companies during the event.
A Spanish dermatology specialty pharmaceutical company, a French major pharmaceutical company, and a global major pharmaceutical company have requested to discuss the clinical trial process in the U.S. and Europe after the Phase III clinical trial of ‘FURESTEM-AD® Inj.’, an atopic stem cell therapy, in Korea.
Interest in ‘FURESTEM-OA Kit Inj.’, which received MRI-based imaging evaluation results for the low-dose arm of the Phase 1 trial in April, is also high. Meetings with a number of European Big Pharma and Korean pharmaceutical companies are also planned, focusing on the results of pain relief in knee osteoarthritis and structural improvement, including cartilage regeneration and inflammation reduction responses.
New pipeline organoids will also be in the mix. A major global pharmaceutical company had a preliminary meeting before the event and confirmed the potential and future of Kangstem Biotech's Organoid technology and requested an additional meeting during Bio USA to discuss in-depth.
In addition, Big Pharma companies from India, China, and other regions have shown interest in Kangstem Biotech's cell therapy technology and are planning to hold partnership meetings.
Meanwhile, Kangstem Biotech is set to announce Phase 3 results for the world's first stem cell therapy for atopic dermatitis, FURESTEM-AD, and Phase 1 results for osteoarthritis, FURESTEM-OA Kit, which can be radically treated with a single injection.